3
Announcements
Trials
Browse
Landscape
Phase
Phase NA
1
Status
Completed
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Gynecologic
1
Genitourinary
1
Gastrointestinal
1
Breast
1
Conditions
Colorectal Neoplasms
5
Breast Neoplasms
4
Prostatic Neoplasms
2
Endometrial Neoplasms
2
Colonic Neoplasms
2
Smoking Cessation
1
Pancreatic Neoplasms
1
Ovarian Neoplasms
1
Neoplasms
1
Motor Activity
1
Melanoma
1
Lung Neoplasms
1
Gastrointestinal Neoplasms
1
Colorectal Cancer Screening
1
Behavior
1
Interventions
pembrolizumab
50
Cyclophosphamide
25
Carboplatin
25
Gemcitabine
20
Cisplatin
19
fludarabine
18
Nivolumab
17
Paclitaxel
16
Bevacizumab
15
Specimen Handling
14
Fluorouracil
11
Magnetic Resonance Spectroscopy
10
aldesleukin
9
Oxaliplatin
9
Irinotecan
9
Docetaxel
9
Biopsy
9
olaparib
8
Trastuzumab
8
durvalumab
7
atezolizumab
7
Hyperthermic Intraperitoneal Chemotherapy
7
Albumin-Bound Paclitaxel
7
Taxes
6
Leucovorin
6
Ipilimumab
6
Interleukin-2
6
Cetuximab
6
Capecitabine
6
130-nm albumin-bound paclitaxel
6
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Ovarian Neoplasms
×
Motivational Interviewing
×
Gastrointestinal
×
Clear all
NCT05162846
2026-03-09
MiGHT
University of Michigan Rogel Cancer Center
Phase NA
Completed
831 enrolled